

# Michail Ignatiadis

---

*WG Member*

Michail Ignatiadis MD, PhD serves as the Director of the Breast Medical Oncology Clinic & Program at the Medical Oncology Department, Institut Jules Bordet (IJB), Hôpital Universitaire de Bruxelles (H.U.B.). He is also associate professor at the Université Libre de Bruxelles. He is leading the Academic Trials Promoting Team (ATPT) and he is member of the Executive and Research Boards of IJB since October 2016

Since January 2021 is the chair of the breast cancer group of the EORTC. From June 2018 to January 2021, he served in the Board of Directors of the EORTC as the chair of the clinical research division.

He has successfully managed the Alexandra/Impassion030 international phase 3 trial of adjuvant atezolizumab in early triple-negative breast cancer. He has been involved in many investigator-initiated trials (IITs) sponsored by IJB at different stages of their development. He has been member of the independent data monitoring committees for international trials and study chair of several IITs and industry sponsored trials. His work in the field of blood-based biomarkers is widely recognized at the international level. He has published more than 130 articles in peer reviewed journals including several papers in high impact factor journals such as JAMA, Journal of Clinical Oncology, Nature Reviews Clinical Oncology, Jama Oncology, Journal of National Cancer Institute, Lancet Oncology.

Prof Ignatiadis is a seasoned medical oncology expert with over two decades of experience in clinical research, leadership and academic excellence.